XGXavier Luke Griffin

Xavier Luke Griffin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xavier Luke Griffin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Warwick Hip Trauma Evaluation One

    by Xavier Griffin

  • Research methods and The Bone & Joint Journal

    by M. L. Costa, D. Stengel, X. L. Griffin, R. Carey Smith, N. Parsons


  • Open Access

    The Warwick Hip Trauma Evaluation – an abridged protocol for the WHiTE Study

    by X. L. Griffin, J. Achten, N. Parsons, F. Boardman, F. Griffiths, M. L. Costa

    Fractures of the proximal femur are one of the greatest challenges facing the medical community, constituting a heavy socioeconomic burden worldwide. The National Hip Fracture Audit currently provides a framework for service evaluation. This evaluation is based upon the assessment of process rather than assessment of patient-centred outcome and therefore it fails to provide meaningful data regarding the clinical effectiveness of treatments. This study aims to capture data from the cohort of patients who present with a fracture of the proximal femur at a single United Kingdom Major Trauma Centre. Patient-centred outcomes will be recorded and provide a baseline cohort within which to test the clinical effectiveness of experimental interventions.


  • Platelet rich therapies for long bone healing in adults

    by Xavier L Griffin, David Wallace, Nick Parsons, Matthew L Costa

    The morbidity and socioeconomic costs associated with long bone healing are considerable. Platelet-rich therapies are autologous blood products with a greater concentration of platelets than physiological whole blood. Despite promising results from a number of in-vitro animal studies, clinical evidence to support the use of platelet-rich therapy in long bone healing is unclear. To assess the effects (benefits or harms) of platelet-rich therapies for treating long bone osteotomies, acute fractures, un-united fractures and defects in adults. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (8 November 2011), the Cochrane Central Register of Controlled Trials (The Cochrane Library, 2011 Issue 4), MEDLINE (1948 to November Week 1 2011) and EMBASE (1980 to Week 44 2011). Trial registers and reference lists of articles were also searched. Randomised and quasi-randomised controlled clinical trials evaluating any type of platelet-rich therapy compared with either no additional treatment or a placebo in the management of long bone osteotomies, acute fractures, un-united fractures and defects in adults. Studies including participants over 18 years of age; reporting functional outcomes, time to union, non-union, secondary procedures such as for fixation failure or delayed or non-union, adverse effects, pain or costs were included. Two authors independently selected the studies for inclusion in the review. Studies were assessed for the risk of bias using The Cochrane Collaboration's 'Risk of bias' tool. Treatment effects for dichotomous outcomes were expressed with risk ratios (RR) and continuous measures with mean differences, together with 95% confidence intervals (CI). Only one eligible study, involving 21 participants, was included. The study compared platelet-rich therapy and allogenic bone graft with allogenic bone graft alone in patients undergoing corrective osteotomy for medial compartment osteoarthrosis of the knee. The risk of bias associated with this study was substantial. There was no significant difference in patient-reported or clinician-assessed functional outcome scores between groups at one year. There was a statistically significant benefit from platelet-rich therapy in the proportion of bones that were united at one year (8/9 versus 3/9; RR 2.67; 95% CI 1.03 to 6.91). This benefit, however, was not maintained when assuming poor outcomes for participants who were lost to follow-up (8/11 versus 3/10; RR 2.42; 95% CI 0.88 to 6.68). One adverse event was reported in a participant receiving platelet-rich therapy.One other eligible study involving hip fracture patients is currently underway. While a potential benefit of platelet-rich therapies to augment long bone healing in adults cannot be ruled out, the currently available evidence from a single trial is insufficient to support the routine use of this intervention in clinical practice. Future trials should focus on reporting patient-reported functional outcomes from all trial participants for a minimum follow-up of one year.


  • Ultrasound and shockwave therapy for acute fractures in adults

    by Xavier L Griffin, Nick Smith, Nick Parsons, Matthew L Costa

    The morbidity and socioeconomic costs of fractures are considerable. The length of time to healing is an important factor in determining a patient's recovery after a fracture. Ultrasound may have a therapeutic role in reducing the time to union after fracture. To assess the effects of low intensity ultrasound (LIPUS), high intensity focused ultrasound (HIFUS) and extracorporeal shockwave therapies (ECSW) as part of the treatment of acute fractures in adults. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (December 2011), the Cochrane Central Register of Controlled Trials (in The Cochrane Library 2011, Issue 4), MEDLINE (1950 to November Week 3 2011), EMBASE (1980 to 2011 Week 49), trial registers and reference lists of articles. Randomised controlled trials evaluating ultrasound treatment in the management of acute fractures in adults. Studies including participants over 18 years of age with acute fractures, reporting functional outcomes, time to union, non‐union, secondary procedures such as for fixation or delayed or non‐union, adverse effects, pain, costs or patient adherence were included. Two authors independently extracted data from the included studies. Treatment effects were assessed using mean differences or risk ratios and, where there was substantial heterogeneity, pooled using a random‐effects model. Results from 'worst case' analyses, which gave more conservative estimates of treatment effects for time to fracture union, are reported in preference to those from 'as reported' analyses. Twelve studies, involving 622 participants with 648 fractures, were included. Eight studies were randomised placebo‐controlled trials, two studies were randomised controlled trials without placebo controls, one study was a quasi‐randomised placebo controlled trial and the remaining study was a quasi‐randomised controlled trial without placebo control. Eleven trials tested LIPUS and one trial tested ECSW. Four trials included participants with conservatively treated upper limb complete fractures and six trials included participants with lower limb complete fractures; these were surgically fixed in four trials. The remaining two trials reported results for conservatively treated tibial stress fractures. Very limited data from two complete fracture studies showed no difference between ultrasound and placebo control in functional outcome. Pooled estimates from two studies found LIPUS did not significantly affect the time to return to training or duty in soldiers or midshipmen with stress fractures (mean difference ‐8.55 days, 95% CI ‐22.71 to 5.61). Based on a 'worst case' analysis, which adjusted for incomplete data, pooled results from eight heterogeneous studies showed no statistically significant reduction in time to union of complete fractures treated with LIPUS (standardised mean difference ‐0.47, 95% CI ‐1.14 to 0.20). This result could include a clinically important benefit or harm, and should be seen in the context of the highly significant statistical heterogeneity (I² = 90%). This heterogeneity was not explained by the a priori subgroup analyses (upper limb versus lower limb fracture, smoking status). An additional subgroup analysis comparing conservatively and operatively treated fractures raised the possibility that LIPUS may be effective in reducing healing time in conservatively managed fractures, but the test for subgroup differences did not confirm a significant difference between the subgroups. Pooled results from eight trials reporting proportion of delayed union or non‐union showed no significant difference between LIPUS and control. Adverse effects directly associated with LIPUS and associated devices were found to be few and minor, and compliance with treatment was generally good. One study reporting on pain scores found no difference between groups at eight weeks. One quasi‐randomised study (59 fractures) found no significant difference between ECSW and no‐placebo control groups in non‐union at 12 months (risk ratio 0.56, 95% CI 0.15 to 2.01). There was a clinically small but statistically significant difference in the visual analogue scores for pain in favour of ECSW at three month follow‐up. The only reported complication was infection, with no significant difference between the two groups. While a potential benefit of ultrasound for the treatment of acute fractures in adults cannot be ruled out, the currently available evidence from a set of clinically heterogeneous trials is insufficient to support the routine use of this intervention in clinical practice. Future trials should record functional outcomes and follow‐up all trial participants. Thérapies par ultrasons et ondes de choc pour les fractures aiguës chez l'adulte Les fractures ont un coût considérable en termes socio‐économiques et de morbidité. Le temps de cicatrisation est un facteur important de la récupération d'un patient après une fracture. Les ultrasons pourraient avoir un rôle thérapeutique dans la réduction du temps nécessaire au ressoudage de l'os après une fracture. Évaluer les effets des thérapies par ultrasons pulsés de faible intensité (LIPUS), par ultrasons focalisés de haute intensité (HIFUS) et par ondes de choc extra‐corporelles (ECSW) dans le cadre du traitement des fractures aiguës chez l'adulte. Nous avons effectué une recherche dans le registre spécialisé du groupe Cochrane sur les traumatismes ostéo‐articulaires et musculaires (décembre 2011), le registre Cochrane des essais contrôlés (dans The Cochrane Library 2011, numéro 4), MEDLINE (de 1950 à la 3ème semaine de novembre 2011), EMBASE (de 1980 à la 49ème semaine de l'année 2011), des registres d’essais cliniques et des bibliographies d'articles. Des essais contrôlés randomisés évaluant l'ultrasonothérapie dans le traitement des fractures aiguës chez l'adulte. Pour être incluses les études devaient porter sur des participants de plus de 18 ans présentant des fractures aiguës et devaient rendre compte des résultats fonctionnels, du temps de ressoudage, de la non cicatrisation, des procédures secondaires (telles que celles exigées pour la fixation, la cicatrisation retardée ou la non cicatrisation), des effets indésirables, de la douleur, des coûts ou de l'observance du traitement par le patient. Deux auteurs ont extrait les données des études incluses de manière indépendante. Les effets des traitements ont été évalués à l'aide des différences moyennes ou des risques relatifs et, lorsqu'il y avait une hétérogénéité importante, le regroupement a été effectué à l'aide d'un modèle à effets aléatoires. Les résultats d'analyse par la méthode du 'cas le plus défavorable', qui génèrent des estimations plus prudentes des effets du traitement sur le temps de ressoudage, sont présentées de préférence aux analyses ne faisant que citer les rapports. Douze études, impliquant 622 participants avec 648 fractures, ont été incluses. Huit études étaient des essais randomisés contrôlés par placebo, deux études étaient des essais contrôlés randomisés sans contrôle placebo, une étude était un essai quasi‐randomisé contrôlé par placebo et la dernière étude était un essai contrôlé quasi‐randomisé sans contrôle placebo. Onze essais avaient testé le LIPUS et un essai avait testé l'ECSW. Quatre essais incluaient des participants ayant des fractures complètes des membres supérieurs traitées de manière conservatrice et six essais incluaient des participants souffrant de fractures complètes des membres inférieurs (celles‐ci avaient été fixées chirurgicalement dans quatre essais). Les deux autres études avaient rendu compte des résultats pour des fractures de stress du tibia traitées de manière conservatrice. Des données très limitées provenant de deux études sur des fractures complètes ne montrent aucune différence entre les ultrasons et le contrôle placebo concernant le résultat fonctionnel. Les évaluations regroupées de deux études ont montré que le LIPUS n'affectait pas significativement le temps nécessaire pour que des soldats ou des aspirants victimes de fractures de stress puissent retourner à leur entrainement ou à leur poste (différence moyenne ‐8,55 jours, IC à 95 % ‐22,71 à 5,61). Sur la base d'une analyse par la méthode du 'cas le plus défavorable', prenant en compte les données incomplètes, les résultats regroupés de huit études hétérogènes n'ont montré aucune réduction statistiquement significative du temps de ressoudage des fractures complètes traitées par LIPUS (différence moyenne standardisée ‐0,47 ; IC à 95 % ‐1,14 à 0,20). Ce résultat pourrait inclure un bénéfice ou un préjudice clinique important et doit être considéré dans le contexte de l'hétérogénéité statistique hautement significative (I² = 90 %). Cette hétérogénéité ne s'expliquait pas par les analyses a priori de sous‐groupes (fracture de membre supérieur versus membre inférieur, consommation de tabac). Une analyse supplémentaire par sous‐groupes, comparant les fractures traitées de manière conservatrice et chirurgicale, a soulevé la possibilité que le LIPUS puisse être efficace dans la réduction du temps de cicatrisation des fractures gérées de manière conservatrice, mais le test des différences entre sous‐groupes n'a pas confirmé leur significativité. Les résultats regroupés de huit essais rendant compte des proportions de cicatrisations retardées et de non cicatrisation n'ont montré aucune différence significative entre le LIPUS et le contrôle. Les effets indésirables directement liés au LIPUS et aux dispositifs associés se sont avérés rares et mineurs ; l'observance du traitement était généralement bonne. Une étude rendant compte des scores de douleur n'avait trouvé aucune différence entre les groupes après huit semaines. Un étude quasi‐randomisée (59 fractures) n'avait trouvé aucune différence significative entre l'ECSW et les groupes de contrôle non‐placebo concernant la non cicatrisation après 12 mois (risque relatif 0,56 ; IC à 95 % 0,15 à 2,01). Il y avait une différence cliniquement faible mais statistiquement significative au niveau des scores visuels analogiques de la douleur, en faveur de l'ECSW, après trois mois de suivi. La seule complication signalée était l'infection, sans différence significative entre les deux groupes. Bien qu'un éventuel bénéfice des ultrasons dans le traitement des fractures aiguës chez l'adulte ne puisse être exclu, les données actuellement disponibles provenant d'une série d'essais cliniques hétérogènes ne sont pas suffisantes pour étayer l'utilisation systématique de cette intervention en pratique clinique. Les futurs essais devraient enregistrer les résultats fonctionnels et suivre tous les participants à l'essai.


  • Platelet rich therapies for long bone healing in adults

    by Xavier L Griffin, David Wallace, Nick Parsons, Matthew L Costa


  • Electromagnetic field stimulation for treating delayed union or non-union of long bone fractures in adults

    by Xavier L Griffin, Matthew L Costa, Nick Parsons, Nick Smith

    Delayed union and non-union of fractures are a considerable cause of morbidity to patients. Laboratory studies have shown that electromagnetic fields can stimulate the formation of new bone, indicating a potential role for electromagnetic stimulation in the treatment of fractures that have failed to heal. To assess the effects of electromagnetic stimulation for treating delayed union or non-union of long bone fractures in adults. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (May 2010), the Cochrane Central Register of Controlled Trials (in The Cochrane Library 2010, Issue 2), MEDLINE (1966 to May 2010) and EMBASE (1980 to 2010 Week 20), trial registers and reference lists of articles. Randomised controlled trials evaluating electromagnetic field stimulation for the treatment of delayed union or non-union of long bones in adults. Two authors independently selected studies and performed data extraction and risk of bias assessment. Treatment effects were assessed using risk ratios and, where appropriate, data were pooled using a random-effects model. Four studies, involving 125 participants, were included. Three studies evaluated the effects of pulsed electromagnetic fields and one study, capacitive coupled electric fields. Participants with delayed union and non-union of the long bones were included, but most data related to non-union of the tibia. Although all studies were blinded randomised placebo-controlled trials, each study had limitations.The primary measure of the clinical effectiveness of electromagnetic field stimulation was the proportion of participants whose fractures had united at a fixed time point. The overall pooled effect size was small and not statistically significant (risk ratio 1.96; 95% confidence interval 0.86 to 4.48; 4 trials). There was substantial clinical and statistical heterogeneity in this pooled analysis (I(2) = 58%). A sensitivity analysis conducted to determine the effect of multiple follow-up time-points on the heterogeneity amongst the studies showed that the effect size remained non-significant at 24 weeks (risk ratio 1.61; 95% confidence interval 0.74 to 3.54; 3 trials), with similar heterogeneity (I(2) = 57%).There was no reduction in pain found in two trials. No study reported functional outcome measures. One trial reported two minor complications resulting from treatment. Though the available evidence suggests that electromagnetic field stimulation may offer some benefit in the treatment of delayed union and non-union of long bone fractures, it is inconclusive and insufficient to inform current practice. More definitive conclusions on treatment effect await further well-conducted randomised controlled trials.


  • Open Access

    Warwick Hip Trauma Study: a randomised clinical trial comparing interventions to improve outcomes in internally fixed intracapsular fractures of the proximal femur. Protocol for The WHiT Study

    by Xavier Luke Griffin, Nick Parsons, Juul Achten, Matthew L Costa

    Controversy exists regarding the optimal treatment for patients with displaced intracapsular fractures of the proximal femur. The recognised treatment alternatives are arthroplasty and internal fixation. The principal criticism of internal fixation is the high rate of non-union; up to 30% of patients will have a failure of the fixation leading to revision surgery. We believe that improved fracture healing may lead to a decreased rate of failure of fixation. We therefore propose to investigate strategies to both accelerate fracture healing and improve fixation that may significantly improve outcomes after internal fixation of intracapsular femoral fractures. We aim to test the clinical effectiveness of the osteoinductive agent platelet rich plasma and conduct a pilot study of a novel fixed-angle fixation system. We have planned a three arm, single centre, standard-of-care controlled, double blinded, pragmatic, randomised clinical trial. The trial will include a standard two-way comparison between platelet-rich plasma and standard-of-care fixation versus standard-of-care fixation alone. In addition there will be a subsidiary pilot arm testing a fixed-angle screw and plate fixation system. Current Controlled Trials ISRCTN49197425